{"PubmedBookArticle": [], "PubmedArticle": [{"MedlineCitation": {"KeywordList": [["Apoptosis", "Breast cancer", "Epirubicin", "Parthenolide"]], "SpaceFlightMission": [], "InvestigatorList": [], "OtherAbstract": [], "OtherID": [], "CitationSubset": ["IM"], "GeneralNote": [], "PMID": "32686017", "DateCompleted": {"Year": "2021", "Month": "06", "Day": "22"}, "DateRevised": {"Year": "2023", "Month": "06", "Day": "15"}, "Article": {"ArticleDate": [{"Year": "2020", "Month": "07", "Day": "20"}], "Language": ["eng"], "ELocationID": ["10.1007/s11033-020-05649-3"], "Journal": {"ISSN": "1573-4978", "JournalIssue": {"Volume": "47", "Issue": "8", "PubDate": {"Year": "2020", "Month": "Aug"}}, "Title": "Molecular biology reports", "ISOAbbreviation": "Mol Biol Rep"}, "ArticleTitle": "Anticancer and apoptotic activities of parthenolide in combination with epirubicin in mda-mb-468 breast cancer cells.", "Pagination": {"StartPage": "5807", "EndPage": "5815", "MedlinePgn": "5807-5815"}, "Abstract": {"AbstractText": ["Breast cancer is the most common malignancy in women worldwide. Unfortunately, current therapeutic methods are not completely efficient. Hence, combination therapy with medicinal plants has attracted several kinds of research. In the current study, we aimed to investigate the apoptotic and anti-cancer effect of Parthenolide in combination with Epirubicin in the MDA-MB-468 breast cancer cell line. In this study, \u00a0the anti-proliferative and pro-apoptotic effect of Parthenolide in combination with Epirubicin and without it, in the MDA-MB-468 cell line have been assessed by MTT test, Hoescht staining and flow cytometry methods. Our outcomes showed that Parthenolide treatment in the present of Epirubicin led to a decrease in the minimum toxic concentration of Parthenolide and Epirubicin in comparison with individual treatments. Then, to achieve a likely molecular mechanism of mentioned drugs Bax and Bcl2 expression level evaluated by Real-time PCR and subsequently, Western blotting has been estimated the protein level of Caspase 3. Our data indicated that the treatment of cells with Parthenolide led to up-regulation of Bax and downregulation of Bcl2 at mRNA level. Moreover, Parthenolide treatment led to the obvious alternation of Caspase3 protein level.\u00a0These\u00a0results indicated that Parthenolide in combination with Epirubicin have significant cytotoxicity due to targeting the main regulators of apoptosis. Hence, according to lack of cytotoxicity of Parthenolide on normal cells that lead to reduction of drug side effects, it could be suggested as an adjuvant therapy with Epirubicin after complementary research on animal model and clinical trial."]}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Biochemistry, School of Medicine, Birjand University of Medical Sciences, Birjand, Iran."}], "LastName": "Ghorbani-Abdi-Saedabad", "ForeName": "Arash", "Initials": "A"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Cellular and Molecular Research Center, Birjand University of Medical Sciences, Birjand, Iran."}, {"Identifier": [], "Affiliation": "Department of Nanomedicine, School of Medicine, Birjand University of Medical Sciences, Birjand, Iran."}], "LastName": "Hanafi-Bojd", "ForeName": "Mohammad Yahya", "Initials": "MY"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Zanjan Metabolic Diseases Research center, Zanjan University of Medical Sciences, Zanjan, Iran."}], "LastName": "Parsamanesh", "ForeName": "Negin", "Initials": "N"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmacodynamics and Toxicology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran."}], "LastName": "Tayarani-Najaran", "ForeName": "Zahra", "Initials": "Z"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Biology, Faculty of Sciences, University of Birjand, Birjand, Iran. hmollaei@birjand.ac.ir."}], "LastName": "Mollaei", "ForeName": "Homa", "Initials": "H"}, {"Identifier": ["0000-0001-7713-3897"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Cellular and Molecular Research Center, Birjand University of Medical Sciences, Birjand, Iran. hooshyar@msu.edu."}, {"Identifier": [], "Affiliation": "Microbiology and Molecular Genetics, Michigan State University, East Lansing, MI, USA. hooshyar@msu.edu."}], "LastName": "Hoshyar", "ForeName": "Reyhane", "Initials": "R"}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "Netherlands", "MedlineTA": "Mol Biol Rep", "NlmUniqueID": "0403234", "ISSNLinking": "0301-4851"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Anti-Inflammatory Agents, Non-Steroidal"}, {"RegistryNumber": "0", "NameOfSubstance": "BAX protein, human"}, {"RegistryNumber": "0", "NameOfSubstance": "BCL2 protein, human"}, {"RegistryNumber": "0", "NameOfSubstance": "Proto-Oncogene Proteins c-bcl-2"}, {"RegistryNumber": "0", "NameOfSubstance": "Sesquiterpenes"}, {"RegistryNumber": "0", "NameOfSubstance": "Topoisomerase II Inhibitors"}, {"RegistryNumber": "0", "NameOfSubstance": "bcl-2-Associated X Protein"}, {"RegistryNumber": "2RDB26I5ZB", "NameOfSubstance": "parthenolide"}, {"RegistryNumber": "3Z8479ZZ5X", "NameOfSubstance": "Epirubicin"}], "MeshHeadingList": [{"QualifierName": ["administration & dosage"], "DescriptorName": "Anti-Inflammatory Agents, Non-Steroidal"}, {"QualifierName": ["pharmacology"], "DescriptorName": "Antineoplastic Combined Chemotherapy Protocols"}, {"QualifierName": ["drug effects"], "DescriptorName": "Apoptosis"}, {"QualifierName": ["drug therapy", "metabolism", "pathology"], "DescriptorName": "Breast Neoplasms"}, {"QualifierName": [], "DescriptorName": "Cell Line, Tumor"}, {"QualifierName": ["drug effects"], "DescriptorName": "Cell Proliferation"}, {"QualifierName": ["drug effects"], "DescriptorName": "Cell Survival"}, {"QualifierName": ["administration & dosage"], "DescriptorName": "Epirubicin"}, {"QualifierName": [], "DescriptorName": "Female"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": ["metabolism"], "DescriptorName": "Proto-Oncogene Proteins c-bcl-2"}, {"QualifierName": ["administration & dosage"], "DescriptorName": "Sesquiterpenes"}, {"QualifierName": ["administration & dosage"], "DescriptorName": "Topoisomerase II Inhibitors"}, {"QualifierName": ["metabolism"], "DescriptorName": "bcl-2-Associated X Protein"}]}, "PubmedData": {"ReferenceList": [{"ReferenceList": [], "Reference": [{"Citation": "Harirchi I, Kolahdoozan S, Karbakhsh M, Chegini N, Mohseni S, Montazeri A et al (2010) Twenty years of breast cancer in Iran: downstaging without a formal screening program. Ann Oncol 22(1):93\u201397", "ArticleIdList": ["20534622"]}, {"Citation": "Tang Y, Wang Y, Kiani MF, Wang B (2016) Classification, treatment strategy, and associated drug resistance in breast cancer. Clin Breast Cancer 16(5):335\u2013343", "ArticleIdList": ["27268750"]}, {"Citation": "Qin S-Y, Cheng Y-J, Lei Q, Zhang A-Q, Zhang X-Z (2018) Combinational strategy for high-performance cancer chemotherapy. Biomaterials 171:178\u2013197", "ArticleIdList": ["29698868"]}, {"Citation": "Arzi L, Riazi G, Sadeghizadeh M, Hoshyar R, Jafarzadeh N (2018) A comparative study on anti-invasion, antimigration, and antiadhesion effects of the bioactive carotenoids of saffron on 4T1 breast cancer cells through their effects on Wnt/\u03b2-catenin pathway genes. DNA Cell Biol 37(8):697\u2013707", "ArticleIdList": ["29969282"]}, {"Citation": "Ebrahimi S, Mollaei H, Hoshyar R (2017) Ziziphus Jujube: a review study of its anticancer effects in various tumor models invitro and invivo. (Noisy-le-Grand. France). Cell Mol Biol 63(10):122\u2013127", "ArticleIdList": ["29096755"]}, {"Citation": "Mollaei H, Safaralizadeh R, Babaei E, Abedini MR, Hoshyar R (2017) The anti-proliferative and apoptotic effects of crocin on chemosensitive and chemoresistant cervical cancer cells. Biomed Pharmacother 94:307\u2013316", "ArticleIdList": ["28763753"]}, {"Citation": "Sauter ER (2020) Cancer prevention and treatment using combination therapy with natural compounds. Exp Rev Clin Pharmacol 13(3):265\u2013285"}, {"Citation": "Hoshyar R, Mahboob Z, Zarban A (2016) The antioxidant and chemical properties of Berberis vulgaris and its cytotoxic effect on human breast carcinoma cells. Cytotechnology 68(4):1207\u20131213", "ArticleIdList": ["25916942"]}, {"Citation": "Prasad S, Gupta SC, Tyagi AK (2017) Reactive oxygen species (ROS) and cancer: role of antioxidative nutraceuticals. Cancer Lett 387:95\u2013105", "ArticleIdList": ["27037062"]}, {"Citation": "Elmore S (2007) Apoptosis: a review of programmed cell death. Toxicol Pathol 35(4):495\u2013516", "ArticleIdList": ["17562483", "2117903"]}, {"Citation": "Inoue-Yamauchi A, Jeng PS, Kim K, Chen H-C, Han S, Ganesan YT et al (2017) Targeting the differential addiction to anti-apoptotic BCL-2 family for cancer therapy. Nat Commun 8(1):1\u201314"}, {"Citation": "Khanzadeh T, Hagh MF, Talebi M, Yousefi B, Azimi A, Baradaran B (2018) Investigation of BAX and BCL2 expression and apoptosis in a resveratrol-and prednisolone-treated human T-ALL cell line, CCRF-CEM. Blood Res 53(1):53\u201360", "ArticleIdList": ["29662863", "5898995"]}, {"Citation": "Yamaguchi N, Fujii T, Aoi S, Kozuch PS, Hortobagyi GN, Blum RH (2015) Comparison of cardiac events associated with liposomal doxorubicin, epirubicin and doxorubicin in breast cancer: a Bayesian network meta-analysis. Eur J Cancer 51(16):2314\u20132320", "ArticleIdList": ["26343314"]}, {"Citation": "Hanafi-Bojd MY, Jaafari MR, Ramezanian N, Xue M, Amin M, Shahtahmassebi N et al (2015) Surface functionalized mesoporous silica nanoparticles as an effective carrier for epirubicin delivery to cancer cells. Eur J Pharm Biopharm 89:248\u2013258", "ArticleIdList": ["25511563"]}, {"Citation": "Rabi T, Bishayee A (2009) d-Limonene sensitizes docetaxel-induced cytotoxicity in human prostate cancer cells: generation of reactive oxygen species and induction of apoptosis. J Carcinogen 8:9"}, {"Citation": "Jafari N, Nazeri S, Enferadi ST (2018) Parthenolide reduces metastasis by inhibition of vimentin expression and induces apoptosis by suppression elongation factor \u03b1\u20131 expression. Phytomedicine 41:67\u201373", "ArticleIdList": ["29519321"]}, {"Citation": "Freund RR, Gobrecht P, Fischer D, Arndt H-D (2020) Advances in chemistry and bioactivity of parthenolide. Nat Prod Rep 37(4):541\u2013565", "ArticleIdList": ["31763637"]}, {"Citation": "Liu M, Xiao C, Sun M, Tan M, Hu L, Yu Q (2018) Parthenolide inhibits STAT3 signaling by covalently targeting janus kinases. Molecules 23(6):1478", "ArticleIdList": ["6100543"]}, {"Citation": "Talib WH, Al Kury LT (2018) Parthenolide inhibits tumor-promoting effects of nicotine in lung cancer by inducing P53-dependent apoptosis and inhibiting VEGF expression. Biomed Pharmacother 107:1488\u20131495", "ArticleIdList": ["30257366"]}, {"Citation": "Carlisi D, Buttitta G, Di Fiore R, Scerri C, Drago-Ferrante R, Vento R et al (2016) Parthenolide and DMAPT exert cytotoxic effects on breast cancer stem-like cells by inducing oxidative stress, mitochondrial dysfunction and necrosis. Cell Death Dis 7(4):e2194-e"}, {"Citation": "Li H, Lu H, Lv M, Wang Q, Sun Y (2018) Parthenolide facilitates apoptosis and reverses drug-resistance of human gastric carcinoma cells by inhibiting the STAT3 signaling pathway. Oncol Lett 15(3):3572\u20133579", "ArticleIdList": ["29467878", "5796286"]}, {"Citation": "Kim S-L, Kim SH, Trang KTT, Kim IH, Lee S-O, Lee ST et al (2013) Synergistic antitumor effect of 5-fluorouracil in combination with parthenolide in human colorectal cancer. Cancer Lett 335(2):479\u2013486", "ArticleIdList": ["23507557"]}, {"Citation": "Valavi M, Saedabad AGA, Hoshyar R, Mollaei H (2018)\u00a0Effects of combined crocin and epirubicin on apoptosis and cell cycle pathways in a human cervical cancer cell line. Int J Cancer Manag, 11(12):\u00a0e82575."}, {"Citation": "Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. Cancer J Clin 61(2):69\u201390"}, {"Citation": "Valko M, Leibfritz D, Moncol J, Cronin MT, Mazur M, Telser J (2007) Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol 39(1):44\u201384", "ArticleIdList": ["16978905"]}, {"Citation": "Dai J, Mumper RJ (2010) Plant phenolics: extraction, analysis and their antioxidant and anticancer properties. Molecules 15(10):7313\u20137352", "ArticleIdList": ["20966876", "6259146"]}, {"Citation": "Wyr\u0119bska A, Szyma\u0144ski J, Gach K, Piekielna J, Koszuk J, Janecki T et al (2013) Apoptosis-mediated cytotoxic effects of parthenolide and the new synthetic analog MZ-6 on two breast cancer cell lines. Mol Biol Rep 40(2):1655\u20131663", "ArticleIdList": ["23065294"]}, {"Citation": "Moumou M, El Bouakher A, Allouchi H, El Hakmaoui A, Benharref A, Mathieu V et al (2014) Synthesis and biological evaluation of 9\u03b1-and 9\u03b2-hydroxyamino-parthenolides as novel anticancer agents. Bioorg Med Chem Lett 24(16):4014\u20134018", "ArticleIdList": ["24998377"]}, {"Citation": "Parada-Turska J, Paduch R, Majdan M, Kandefer-Szersze\u00f1 M, Rzeski W (2007) Antiproliferative activity of parthenolide against three human cancer cell lines and human umbilical vein endothelial cells. Pharmacol Rep 59(2):233", "ArticleIdList": ["17556802"]}, {"Citation": "Sohma I, Fujiwara Y, Sugita Y, Yoshioka A, Shirakawa M, Moon J-H et al (2011) Parthenolide, an NF-\u03baB inhibitor, suppresses tumor growth and enhances response to chemotherapy in gastric cancer. Cancer Genomics-Proteomics 8(1):39\u201347", "ArticleIdList": ["21289336"]}, {"Citation": "Cheng G, Xie L (2011) Parthenolide induces apoptosis and cell cycle arrest of human 5637 bladder cancer cells in vitro. Molecules 16(8):6758\u20136768", "ArticleIdList": ["21829151", "6264178"]}, {"Citation": "Lee CS, Kim YJ, Lee SA, Myung SC, Kim W (2012) Combined effect of H sp90 inhibitor geldanamycin and parthenolide via reactive oxygen species-mediated apoptotic process on epithelial ovarian cancer cells. Basic Clin Pharmacol Toxicol 111(3):173\u201381", "ArticleIdList": ["22433057"]}, {"Citation": "Trang KTT, Kim S-L, Park S-B, Seo S-Y, Choi C-H, Park J-K et al (2014) Parthenolide sensitizes human colorectal cancer cells to tumor necrosis factor-related apoptosis-inducing ligand through mitochondrial and caspase dependent pathway. Intest Res 12(1):34", "ArticleIdList": ["4204686"]}, {"Citation": "Lan B, Wan Y-J, Pan S, Wang Y, Yang Y, Leng Q-L et al (2015) Parthenolide induces autophagy via the depletion of 4E-BP1. Biochem Biophys Res Commun 456(1):434\u20139", "ArticleIdList": ["25482447"]}, {"Citation": "Kreuger MRO, Grootjans S, Biavatti MW, Vandenabeele P, D\u2019Herde K (2012) Sesquiterpene lactones as drugs with multiple targets in cancer treatment: focus on parthenolide. Anti-Cancer Drugs 23(9):883\u2013896", "ArticleIdList": ["22797176"]}, {"Citation": "Kim H-Y, Kim S-L, Park Y-R, Liu Y-C, Seo SY, Kim SH et al (2015) Balsalazide potentiates parthenolide-mediated inhibition of nuclear factor-\u03baB signaling in HCT116 human colorectal cancer cells. Intest Res 13(3):233"}]}], "History": [{"Year": "2020", "Month": "4", "Day": "28"}, {"Year": "2020", "Month": "7", "Day": "8"}, {"Year": "2020", "Month": "7", "Day": "21", "Hour": "6", "Minute": "0"}, {"Year": "2021", "Month": "6", "Day": "23", "Hour": "6", "Minute": "0"}, {"Year": "2020", "Month": "7", "Day": "21", "Hour": "6", "Minute": "0"}], "PublicationStatus": "ppublish", "ArticleIdList": ["32686017", "10.1007/s11033-020-05649-3", "10.1007/s11033-020-05649-3"]}}]}